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Summary 
In MILL mice, the mostly recessive lpr mutation results in both the accumulation  of CD4-, 
CD8-,CD3 + T cells in lymphoid tissue and many features of generalized autoimmune disease, 
including immune complex glomerulonephritis. To positionally done the lpr mutation and analyze 
the effects of  background genes, backcross offspring were examined from the cross: (MRL/MpJ- 
Ipr  x  CAST/Ei)Fa  x  MRL/MpJ-Ipr.  The Ipr gene was found to be closely linked to a mouse 
chromosome 19 marker defined by a variation of a Fas gene restriction fragment. Our results 
identified differences in ILNA expression and differences in the genomic organization  of the Fas 
gene between normal and lpr mice, and confirm the recent report that a mutation in the Fas 
apoptosis gene is the Ipr mutation. However, our results also indicate that the Fas gene is expressed 
in spleen cells from normal mice, and spleen and lymph node ceils from mice with a second 
mutation at the Ipr locus (Ipr%  Together these results suggest  that altered Fas transcription 
results in the failure of lymphocytes  to undergo programmed cell death and may lead to an altered 
immune cell repertoire.  This mechanism may explain certain central and peripheral defects in 
tolerance that are present in autoimmune disease. The current study also demonstrates the profound 
effect of  background genes on the degree of nephritis, lymphadenopathy, and anti-DNA antibody 
production. Of major note, our studies suggest the identification of chromosomal positions for 
genes that modify nephritis.  Analysis of the backcross mice for markers covering most of the 
mouse genome suggests that over 50% of the variance in renal disease  is attributable to quantitative 
trait loci on mouse chromosomes 7 and 12. Moreover, this study provides a model for dissecting 
the complex genetic interactions  that result in manifestations  of autoimmune disease. 
T 
he pathogenesis  of generalized autoimmune disease is 
determined in large part by genetic predisposition. Studies 
of families with either SLE or Sjogren's disease have demon- 
strated the importance of heredity and suggest that multiple 
genetic factors result in a variety of clinical features (1). Al- 
though animal models with single gene defects would pro- 
vide the simplest models to study the role of non-MHC genes 
in the development  and/or potentiation of autoimmunity, 
a more in-depth analysis indicates that the manifestation of 
disease results from a complex interaction of genes (reviewed 
in reference 2). This study provides insight into a single gene 
defect (Ipr) and develops an approach to dissect the genetic 
basis of non-MHC-mediated immunopathogenesis of autoim- 
mune disease. 
Single gene defects that lead to or accelerate autoimmune 
disease include the mouse autosomal recessive mutation/_pr 
(lymphoproliferation)  (3, 4)  that was recently mapped to 
mouse chromosome (Chr)q9 (5). MRL/MpJ mice homo- 
zygous for the lpr mutation produce large amounts of anti- 
DNA antibodies, and develop massive lymphadenopathy, se- 
1  Abbreviations  used in this  paper: Chr, chromosome;  ds, double stranded; 
RFLP, restriction  fragment  length  polymorphism;  ss, single  stranded;  QTL, 
quantitative trait locus. 
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references 2 and 6). MILL mice without the lpr mutation de- 
velop a late onset autoimmune syndrome suggesting that Ipr 
accelerates  rather than causes disease (2). This suggestion is 
further supported by the finding that laboratory strain mice 
that  carry  the  Ipr mutation  develop  much  less  profound 
manifestations of autoimmune disease than MRL-Ipr mice (7). 
Homozygous Ipr mice  are phenotypically  similar  to  mice 
homozygous for the non-allelic gld (generalized lyrnphprolifer- 
ative disease)  mutation (8), and the compound Ipr/+~gld/+ 
heterozygote is phenotypically normal (2). However, a new 
mutation at the Ipr locus, lpr% has recently been described 
that complements gld (9). Although mice with the Ipr, lpr% 
or gld mutations may not mimic precisely a specific human 
autoimmune  disease,  they nevertheless  represent  excellent 
models of SLE with regard to serologic and immunopatho- 
logic features of disease  (6). 
The lymph nodes of most Ipr/lpr mice are heavily popu- 
lated with dull Thy-1 + ,dull CD5,CD4- ,CD8 -  cells. These 
ceils have nonclonal rearrangements  of TCR genes (8,  10). 
In addition, the cells have high expression of cell surface an- 
tigens CD45(B220), Ly-6, CD44, and PC-l, and absent ex- 
pression of surface (s)Ig, Th B, and Ia (8).  Previous studies 
also have established that lymph node cells from Ipr/Ipr mice 
express large amounts of the myb proto-oncogene, which is 
ordinarily only expressed at high levels in the thymus or after 
mitogenic stimulation of T cells (11). In addition, lpr/Ipr pe- 
ripheral T cells display abnormalities in phosphorylation of 
part of the TCR complex (12).  Thus,  these cells represent 
a unique abnormal T cell subset not seen in easily detectable 
numbers in normal mice. However, these abnormalities may 
reflect secondary and tertiary events that are part of a cascade 
resulting from the primary defect. In fact, most studies have 
failed to show that the expanded double-negative T cell popu- 
lation  found in lpr/lpr mice has any function  (13). 
Although the lpr mutation derived its name from the hy- 
pothesis that it causes lymphoprolfferation, subsequent studies 
have failed to show increased mitotic activity of the abnormal 
cells in vivo (14). Rather, results have led to the suggestion 
that the accumulation of the abnormal T cells is derived from 
a defect in the thymic selection process, because most pre-T 
cells are destined to die by apoptosis (15).  Analysis of mice 
transgenic for a TCR specific for the H-Y plus self-antigen 
also has suggested a partial abnormality in negative intrathymic 
selection (16). Examination of TCR VB repertoire in Ipr/Ipr 
mice similarly has suggested a partial abnormality in positive 
selection (17,  18). 
The current  study was initiated in a dual effort to posi- 
tionally clone the Ipr mutation and define the effects of back- 
ground genes in the manifestation  of disease.  The analyses 
presented here of linkage relationships,  genomic structure, 
and RNA expression confirm the suggestion of Watanabe- 
Fukunaga et al.  (19) that a mutation in the Fas gene is the 
Ipr mutation  (19).  Our results differ from theirs,  however, 
in methodology and in important details concerning Fas gene 
expression. Moreover, our study examines the complex genetics 
of lpr-associated autoimmune disease,  and strongly suggests 
the identification of renal disease modifying loci on Chrs 7 
and 12, explaining much of the large variation in renal dis- 
ease observed in backcross mice homozygous for the MRL/ 
MpJ-Ipr allele. 
Materials and Methods 
Mice 
MRL / MpJ-Ipr (MRL.Ipr), MRL/MpJ-+  (MRD+), Mus mus- 
culus castaneus (CAST/Ei),  and  (MRDlpr x  CAST/Ei)F1 mice 
were  bred  at  The  Jackson  Laboratory  (Bar Harbor,  ME). 
CBA/KIJms  (CBA) and CBA/K1Jms-lpr'e (CBA-lprq) mice were 
maintained at the Laboratory Animal Research Center, University 
of Tokyo. Reciprocal backcross mice produced  from mating  in- 
volving (MRL-Ipr x  CAST/Ei)F~ and MRblpr mice were pro- 
duced at The Jackson Laboratory and maintained along with pa- 
rental control mice at the Duke University Vivarium barrier facility. 
Phenotypic Markers 
Three measurements were performed (total lymphoid weight, 
degree of nephritis, anti-DNA antibody titer) as terminal studies 
on MRL.Ipr, (MRDIpr  ￿  CAST/Ei)F1,  and  the  [(MRL-Ipr  x 
CAST/Ei)F1  ￿  MRL-lpr] interspecific backcross mice at 20 wk of 
age. To minimize the variance in the genetically identical parental 
mice, both the lymphoid mass and nephritis index were expressed 
as log transformations. The terms LPR and non-LPR phenotype 
are used within the manuscript to refer to mice that have pheno- 
types characteristic of MRDIpr (lpr/Ipr) or (MRDIpr x  CAST/ 
Ei)F1 (Ipr/+) mice, respectively. 
Lymphoid Mass Index.  This value represents the log10 of the 
total lymphoid  (lymph node plus spleen) weight (in grams) plus 
a constant of 0.97. The constant was added to minimize the effect 
of small variation  in  weight  measurements  among  phenotype- 
negative animals. The addition of this constant before log transfor- 
mation  yields a minimum  value of zero for this index. 
Nephritis Index.  Kidney sections were stained with hematox- 
ylin and eosin and the histopathology assessed  by a single observer. 
This nephritis index represents the log~0 of the additive scores of 
kidney sections graded on a 0-4 scale for intensity of glomerular 
cell infiltrate, and for the presence of glomerular cellularity, glo- 
merular crescents, glomerular  necrosis, tubular casts, and diffuse 
interstitial infiltrates (where 0 represents no abnormality, and 1, 
2, 3, and 4 represent mild, moderate, moderately severe, and severe 
abnormalities, respectively). Both the MRDlpr parental mice and 
interspecific backcross mice varied with respect to these individual 
disease parameters. However, there was no more variability in the 
backcross mice that had nephritis index values in the range of the 
MRDIpr parental mice than in the MILL-Ipr  parental mice them- 
selves (data not shown). Thus, it is likely that separate genetic factors 
are not responsible for the different measurements used to deter- 
mine the extent  of renal disease. 
Anti-DNA Antibodies.  IgG antibodies to single-stranded (ss) 
and double-stranded (ds) DNA were assayed by ELISA using calf 
thymus DNA (Sigma Chemical Co., St. Louis, MO) coated on 
96-well polystyrene microtiter plates (Dynatech, Chantilly, VA) as 
previously described (20). Briefly, sera were added in serial dilu- 
tions in PBS-Triton X-100 (PBS-T) (Sigma Chemical Co.) followed 
by goat anti-mouse IgG peroxidase (Sigma Chemical Co.) diluted 
in PBS-T. After incubation, trimethylene-bis (4-formylpyridinium) 
(TMB) substrate (Sigma Chemical Co.) was added, and the absor- 
bancies at 380 nm were determined on a plate reader, ssDNA used 
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immersion in ice. dsDNA was obtained by treating the DNA prep- 
aration with $1 nuclease. The dsDNA preparation used showed 
no reactivity by ELISA using a mouse mAb specific for ssDNA. 
Southern Blot Hybridization 
DNA from backcross mice was extracted  from tissues using stan- 
dard  techniques and  digested  with  restriction  endonucleases 
(Boehringer Mannheim Biochemicals,  Indianapolis, IN). 10/~g of 
each sample was subjected to electrophoresis on 0.9% agarose gels 
and transferred to Nytran membranes (Schleicher  & Schuell, Inc., 
Keene, NH). Hybridization of probes onto membranes  was accom- 
plished at 65~  and washed under stringent conditions (21) for 
mouse probes (0.2x  SSC at 65~  and reduced stringency (0.Sx 
SSC at 55~  for human probes. 
Hybridization Probes 
All probes were labeled by a hexanucleotide technique with c~- 
[32p]dCTP (3,000 Ci/mmol; New England Nuclear, Boston, MA) 
using an oligolabeling  kit and protocol from Pharmacia  Fine Chem- 
icals (Piscataway,  NJ). 97 clones that define 108 loci were used to 
establish informative markers on each mouse autosome. The clones 
used for spedfically  cited chromosomal markers are listed in Table 
1. The unpublished clones included: L15 for Lyw-57 (lymphocyte 
antigen workshop-57, kind gift of P. Cohen, University of North 
Carolina, Chapel Hill, NC); bMT008 for D12Sell (DNA segment, 
Chr 12, Seldin-1), a clone randomly selected  from a mouse thymus 
cDNA library (Stratagene, La Jolla, CA); and MJ55 for D19SeI3 
(DNA segment, Chr 19, Seldin-3), a genomic clone derived from 
a flow sorted mouse Chr 19 library (38). In addition, several  clones 
were derived  by PC1L  amplification  of  Fas sequences from a mouse 
thymus cDNA library (Stratagene). Clones include: FasLIlL2, a 
3' PCR-amplified probe that contains bp 646-1,405 of the pub- 
lished cDNA sequence (39); FasL2S2, a 5' PCR-amplified probe 
that included bp 32-239; and FasS1S9, a PCR-amplified  probe that 
includes bp 220-665. A 3'-actin clone (40) was used as a control 
for Northern blot analysis. 
Genomic and cDNA inserts from each clone were prepared by 
restriction endonuclease digestion and gel purification, or gener- 
ated by PCR using oligonucleotide primers derived from plasmid 
sequences flanking the insert cloning site. Restriction fragment 
length polymorphisms (RFLPs) were defined that distinguished 
the two parental strains, MRDI~ and CAST/El; those used in segre- 
gation analyses are listed for specifically  cited clones in Table 1. 
Northern Blot Analysis 
Total 1LNA was prepared from mouse tissues and separated on 
formaldehyde agarose gels according to standard techniques (21). 
Briefly, 20/~g of total RNA was loaded onto 1% agarose gels and 
separated at 1 V/cm for 14 h, stained with acridine orange, and 
transferred to Nytran Plus nylon membranes. Northern blots were 
hybridized  under the same  conditions as described  in Southern Blot 
Hybridization,  and washed at high stringency. 
PCR Assays 
The presence of the Fas gene transcript was assayed  using PCR. 
First, polyadenylated  RNA was reverse transcribed with AMV re- 
verse transcriptase  (Boehringer Mannheim  Biochemicals) and 
oligo(dT) primers. First-strand cDNA was quantified and subse- 
quently used as template in a 50-/~1 PCR reaction containing 1-20 
ng of cDNA, 1.0/~M of primers, 200/~M dNTPs, 10 mM Tris- 
HCI, pH 8.3, 50 mM KC1, and 1.25 U ampliTaq  polymerase  (Perkin 
Elmer Cetus, Norwalk, CT).  Primers used spanned nucleotides 
646-675 (L1), 1385-1405 (R2), 32-52 (L2), 239-220 ($2), 220-239 
($1), and 470-451 ($4) of the published mouse Fas sequence (40). 
The standard PCR cycling profile consisted of 40 cycles of 94~ 
for 1 min, 55~  for 1 rain, and 72~  for 1 min. PCR samples 
without template or Taq polymerase  were irradiated  for 3 min with 
short-wave UV light 5 cm from the source before temperature cy- 
cling. 10/~1 of the completed PCR reaction was subjected to elec- 
trophoresis on 1.5% agarose gels for analysis. 
Linkage and Quantitative Trait Locus Analysis 
Gene linkage and genetic maps were determined applying the 
MAPMAKEK computer package  using the Kosambi  mapping func- 
tion (41). The MAPMAKEIL QTL computer package developed 
by Lander and Botstein (42) was used to analyze the backcross data 
for the presence of renal disease modifying loci. This computer 
package divides each chromosome into intervals between mapped 
markers and then calculates the maximum likelihood that a quan- 
titative trait locus (QTL) is present within these intervals. This 
program examines the intervals between mapped loci and calcu- 
lates the most likely phenotypic effect if a linked QTL is present. 
A logarithm of odds (IX)D) score is calculated that reflects the 
strength of evidence for the presence of a QTL. The program also 
computes the proportion of variance that can be explained by the 
putative QTL. Several  considerations  are important in determining 
the appropriate level of significance,  including map length and in- 
terval size. For the current study, which examined "~1,100 cM at 
a median interval of ",,12 cM, a LOD of >2.5 was determined to 
correspond to an overall  false-positive  rate of <5% (see reference  42). 
Results 
Close Linkage of the Fas Gene and the lpr Mutation.  To 
confirm the chromosomal assignment of the Ipr gene and fur- 
ther  define  linkage  relationships  necessary  for  positional 
cloning,  (MRL-Ipr  x  CAST/El)F1  x  MILL-Ipr backcross 
mice were analyzed. CAST/El, an inbred strain derived from 
Mus muscutus castaneus mice, rather than an inbred laboratory 
strain,  was  chosen  as  the  second parent  to  enhance  the 
identification of variant genetic markers. The phenotype of 
individual mice (LPR vs. non-LPR) was determined at 20 
wk of age by measurement of  lymph node plus spleen weight 
(lymphoid mass) and anti-dsDNA autoantibody levels. These 
segregation analyses indicated that the expression  of the Ipr 
gene was influenced by background genes. For example, only 
48 of 182 backcross  mice had lymphoid mass index values 
within 2 SD of the mean of MRL-lpr parental mice (com- 
pared with 17 MRDIpr parental mice similarly housed, each 
of which had values  within 2  SD).  This  number  (48)  is 
significantly less than the expected number of backcross mice 
(91) predicted to be lpr homozygotes (X  2 =  40.6, p < 0.001, 
1 degree of freedom [d.f.]). Conversely, 137 of 182 backcross 
mice had at least modest lymphadenopathy (compared with 
24  [MRL-Ipr  x  CAST/El]F1  mice  similarly  housed), 
significantly greater than the expected number of backcross 
mice (91) predicted to have no lymphadenopathy for a single 
Mendelian recessive  gene (X  2  -  46.5, p  <0.001,  1 d.f.). 
Nevertheless,  84 of 182 backcross mice could be dassified as 
having the LPR or the non-LPR phenotype (see below). 
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Restriction  MRL-Ipr  CAST/Ei 
Genes  Locus  Clone  Reference  enzyme  bands  bands 
kb 
2.3  2.1 
6.8  6.0 
~-1  adrenergic receptor  Adrb-1  ~-1  22  TaqI 
DNA segment,  mouse Chr  12,  New York  D12Nyu3  M13p20-1  23  EcoRI 
University 3 
DNA  segment,  mouse Chr  12,  Sddin  1  DI2Sell  bMT008  This report  MspI  4.1  4.6 
DNA segment,  mouse Chr  19,  Seldin  3  D19SeI3  MJ55  This report  TaqI  7.2  4.6 
Epidermal growth factor binding protein  Egfl~  MB2-12A  24  TaqI  9.4,  6.2  9.8,  8.5 
Fas antigen  Fas  PasLIR2  This report  TaqI  1.4  2.1 
Ghcagon  Gcg  pshghI  25  TaqI  1.8  2.5 
High mobility group protein  14-related  Hmg14-rs7 pM14c  26  TaqI  -*  1.9" 
sequence 7 
Insulin degrading enzyme  lde  Ide-pSRalph a  TaqI  6.6  5.4 
Ig heavy chain  Igh  pC/z  TaqI  11.0,  5.0  6.6,  4.0 
Insulin 2  Ins-2  pB12MI  MspI  2.2  1.9 
Insulin 2-related sequence  1  Ins-2rsl  pB12MI  BamHI  6.0  2.2 
Integration site 2  Int-2  BK4  BamHI  3.0  2.4 
Laminin b  1  Lamb-1  PpE386  MspI  5.0  2.6 
Lymphocyte antigen,  workshop-57  Lyw-57  L15  BamHI  6.8  5.0 
27 
28 
29 
29 
30 
31 
Unpublished 
clone (kind 
gift of P. 
Cohen) 
Membrane metallo-endopeptidase  Mrae 
Oxysterol binding protein  Osbp 
Octamer-specific DNA binding protein  2  0(-2 
Protein  kinase C,  3,  Pkcg 
Pro-opiomdanocortin gene 2  Pomc-2 
Ribosomal protein L18-rdated  sequence 9  Rpl18-rs9 
CD10cDNA  32  MspI  12.0  4.3 
pB + 2.5  33  TaqI  8.0  2.4 
Pac-3-1  34  TaqI  3.8  2.3 
phPKC-3"  35  TaqI  4.4,  2.8  2.6,  4.2 
Pomc eDNA  36  MspI  1.8  2.2 
pL18  37  TaqI  -*  2.8* 
* These clones detect multiple pseudogenes that segregate to positions on several  chromosomes.  The informative  CAST/Ei restriction fragment is indicated. 
A  Chromosome19Haplotypes 
o.p  iDmDmsn~n[]n[]msm~ 
Pomc-2  m[][]mi[]m[]m[]m[]mDm~ 
D195e13  mD[]m~mmDm~mDm~mg 
~,  m%Dm~mDimDusiDm~ 
i0o  m~DmgmDi~mmDmDms 
t,.-6,  N~[]N~NDNDNDNIDN~ 
,..-2,.,  msDn~m~mDmDm~mms 
Ad,)-~  m  )  ~  m  ~  m  ~  I  ~  I  ~  m  N  i  ~  I 
number  of  backcross  mice  32  33  0  2  1  4  9  4  I  I  2  1  6  9  4  1 
B  LPR  backcross  mice  C  non-LPR  backcross  mice 
O,,Se,,  ￿9  :  ￿9  []  ￿9  ,,,,,s,,,  ￿9  :  ￿9  :  m  : 
35  0  0  3  1  0  0  42  2  0  0  1 
Figure  1.  Segregation of the Ipr mutation with the 
Fas apoptosis gene in (MRL-Ipr x  CAST/El)F1  x 
MRblpr backcross mice. For each locus (indicated on 
the left hand side of each row) the failed boa~s repre- 
sent those mice typed as MILblpr homozygotes, and 
the open boxes represent those that typed as the het- 
erozygote F1 pattern.  The number of mice with a 
given haplotype pattern is shown at the bottom of 
each column. (.4) Complete haplotype data for 110 
interspedic back~oss mice fully typed for mouse Chr 
19 markers. (B and C) Segregation  of those mice charac- 
terized as LPR and non-LPR phenotype using strin- 
gent criteria established by the analysis of backeross 
mice with nonrecombinant chromosomes. A total of 
182 mice were examined, 84 of which fulfilled these 
criteria. 
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mouse Chr 19 (5), we analyzed the segregation of lpr using 
markers that map to this chromosome (Os~ Point-2, D19SeB, 
Fas, Ide, Lyw-57, Ins-2rsl, and Adrb-1 [39, 43; andJ. M. Rochelle 
and M. F. Seldin, unpublished data]). Informative RFLPs were 
determined by analysis of the parental mice (Table 1). Haplo- 
type analysis was then performed for each of the 182 bach 
cross mice, resttlting in the genetic map shown in Fig. 1 A. 
Since the manifestations of autoimmune disease, including 
lymphadenopathy and anti-dsDNA antibodies, can be in- 
fluenced by background genes, criteria for LPtL and non-LPR 
phenotype mice were established by analysis of those back- 
cross mice that inherited a nonrecombinant Chr 19 from the 
Ft parent (Fig.  1 A, columns I  and 2), as follows:  32 mice 
that were homozygotes for all Chr 19 markers derived from 
the MRL parental genome defined the upper limit of the 
non-LPR phenotype (lymphoid mass, 0.1 g; and anti-dsDNA 
antibodies, 1,200),  and 33 mice that were heterozygous for 
all Chr 19 markers defined the lower limit for the LPR pheno- 
type designation (lymphoid mass,  2.5 g; and anti-dsDNA 
antibodies, 1,750). None of the 84 backcross mice classified 
as LPR or non-LPR by these criteria inherited a crossover 
between lpr and the Fas genes, as shown by haplotype anal- 
),sis (Fig.  1, B and C). In addition, when all backcross mice 
were examined, the MAPMAKER QTL program indicated 
maximum LOD scores at the Fas locus for the measurement 
ofanti-ssDNA (LOD, 17.8), anti-dsDNA (LOD, 30.5), lyre- 
phoid mass (LOD, 36.7), and nephritis (LOD 17.4). We con- 
dude that the liar  mutation is closely linked to the Fas gene. 
Analysis of Fas RNA  Expression Shows Abnormal  Transcrip- 
tion in MRL, Ipr Mic~  The above mapping data together with 
the previously defined functional data suggested that an al- 
teration in the Fas gene accounts for the phenotypic changes 
observed in Ipr homozygous mice. Therefore, Fas expression 
was analyzed by Northern blotting of total RNA purified 
from several different tissues obtained from MILL-+, MILL- 
liar, CBA,  CBA-Ipr%  C3H-+,  and C3H-gld mice. Using a 
3' Fas eDNA probe (FasL1R2), high-level Fas expression was 
demonstrated in liver from MILL-  +  mice, CBA- +, and CBA- 
lprC~ mice (Fig.  2).  Moderate expression of the 2.1-kb/:as 
transcript  was  evident in  lymphoid tissue from MILL-+, 
CBA-+, and CBA-Ipr'~ and C3H-g/d mice. In contrast, com- 
pared with MILL-+ mice, the expression of  Fas was markedly 
lower in liver, spleen, and lymph node tissues from Ipr homozy- 
gous mice (Fig.  2).  Finally, longer exposures  of Northern 
membranes suggested that a low level ofFas gene expression 
occurred in tissues from Ipr homozygous mice. 
To further analyze the expression of Fas in normal and Ipr/Ipr 
mice, PCR assays were performed from cDNA obtained by 
reverse  transcription  of  the  RNA  samples.  The  PCR 
amplification of several segments of the Fas gene using strin- 
gent annealing conditions demonstrated that Fas was tran- 
scribed in lpr/lpr spleen and lymph node cells (Fig. 3). Addi- 
tionally, quantitative PCR experiments using titrated amounts 
of cDNA template and a smaller number of PCR cycles sug- 
gest that similar amounts of the Fas transcript are made in 
normal and Ipr/Ipr lymphoid tissue (not shown). However, 
in addition to amplifying fragments of the predicted size, aber- 
rantly sized PCR fragments were obtained with some of the 
primer pairs (e.g., Fig. 3 B). Notably, the PCR primer pairs 
used to amplify nudeotides 220-470  ($1-$4, 250 bp) and 
220-665 (S1-$9, 445 bp) of the published  Fas cDNA sequence 
produced additional PCR fragments of 450 bp (Fig. 3 B) and 
650 bp (not shown), respectively, suggesting that the Fas tran- 
Figure 2.  Northern blot hybridization of RNA from MRL-Ipr,  CBA- 
Ipr,g, C3H-g/d, and congenic controls with a 3' Fas apoptosis gene probe 
(FasLIR2).  Fas gene e~pression  (top) is compared with  3~-actin (Actg), 
(middle) and acridine  orange staining of total RNA (bottom) for the fol- 
lowing samples:  (1) CBA-+  spleen,  (2) CBA-lpr~g spleen,  (3) CBA-Ipr,g 
lymph node, (4) MRD +  spleen,  (5) MKMpr spleen,  (6) MRL-Ipr lymph 
node,  (7) MRL-Ipr liver, (8) CBA-+  liver, (9) CBA-Ipr,8  liver, (10) MRL,+ 
liver, (11) C3H-+  liver, (12) C3H-+  thymus, (13) C3H-g/d lymph node. 
Sizes of the transcripts were 2.1  kb (Fas) and 0.7 kb (Actg). 
Figure 3.  PCR amplification of the Fas eDNA segments. The tem- 
plates were reverse transcribed KNA (20 ng of oligo(dT)-primed eDNA) 
from MRD +  spleen (lane I), MRDIpr spleen (lane 3), and MRDIpr lymph 
node tissue (lane 5). Three partially overlapping segments of the Fas gene 
were amplified  using the following primers: (A) L2 and $2 (bp 32-239 
of the published sequence; reference 19); (/3) $1 and $4 (bp 220-470); and 
(C) L1 and R2 (bp 646-1405).  Alternate lanes (2 and 4) contained PCR 
control reactions in which no template was added.  Results were verified 
by examination of RNA samples derived from multiple individual mice. 
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Probes used for Northern hybridizations were derived using either MILL-+ 
(A) or MRL.Ipr (B) cDNA as template for PCK amplification. The region 
amplified represented a 3' segment  (FasLIK2,  bp 646-1405)  of the Fas 
gene. In A, the wild-type probe detects bands in MRL-+ liver (lane 3), 
but not MRL-Ipr spleen, lymph node, or liver (lanes l, 2, and 4). In B, 
the Ipr probe detects bands in MRL +  liver (lane 3), and also hybridizes 
to transcripts in M1LL-Ipr  spleen (lane 1) and lpr lymph node (lane 2), but 
does not detect bands in lpr liver (lane 4). Additional  higher molecular 
weight bands are detected by the Ipr-derived probe in Ipr spleen and lymph 
node (lanes 1 and 2). 
scripts in Ipr/Ipr mice contained additional and disparate se- 
quences  from the functional Fas transcript. 
The MRL-Ipr and MILL +-derived amplified products were 
gel purified and used as probes for both genomic and Northern 
blot hybridization.  The amplified fragments from both MR.b 
Ipr and MRL-+  detected the same Fas genomic restriction 
bands that were previously observed using amplified prod- 
ucts from a wild-type thymus cDNA library, indicating that 
the fragments amplified from transcribed sequences were de- 
rived from the same region of the genome in both strains 
(MILL-+  and  MRDIpr)  (data  not  shown).  In  contrast, 
Northern blot analysis showed different expression patterns 
when lpr-derived probes, as compared with wild-type thymus 
cDNA probes and MR.b +-derived probes,  were used.  For 
example, when the Ipr-derived fragment (FasL1R2) was used 
as a probe prominent transcripts of 2.3 and 4.5 kb were ob- 
served in MILblpr spleen and lymph node tissue (Fig. 4). These 
differences in hybridization patterns indicate that the frag- 
ments amplified from mRNA in lpr mice contain sequences 
not present in transcripts from wild-type mice. These results 
combined with the PCR results and genomic blot analysis 
strongly suggest that mRNA processing of the Fas gene is 
different in MRL-Ipr mice. 
Genomic Restriction Analyses Identify a Deletion within the 
Fas Gene of Ipr/Ipr mice.  Genomic DNA digests were per- 
formed to examine whether a structural mutation was present 
in the Fas gene of Ipr/Ipr mice that might explain the differ- 
ences noted in Fas RNA transcripts in cells from lpr/Ipr  mice. 
DNAs were digested with multiple restriction endonudeases 
and examined by Southern blot analysis  using several  Fas probes 
(FasL1R2, FasL2S2, and FasS1S9). The FasS1S9 probe detected 
multiple differences between MRDIpr and MRL-+  DNA 
samples (e.g., see Fig. 5). Double digests defined a genomic 
restriction map in MR.b+ and MRL-IFr  DNA (Fig. 5). These 
analyses indicate that a 1.4-kb  fragment of the Fas gene is 
deleted in the lpr/Ipr  mouse and, together with the PCR anal- 
yses (see above), suggest that the deletion is probably within 
a Fas intron. 
Complex Genetic Interactions Underlie the Manifestations of 
Autoimmune Disease.  The identification of the Fas gene as 
the site of the Ipr mutation also allows the separation of back- 
cross mice into homozygotes and heterozygotes for Ipr. The 
phenotypic characteristics  of Ipr/lpr and Ipr/+ (MRI~lpr  x 
CAST/Ei)F1  x  MILL-Ipr backcross  mice were  compared 
with those of the MRblpr  parental and the (MRL-Ipr  x 
CAST/Ei)F1 mice (Table 2). The standard deviation for lym- 
phoid mass and renal disease of Ipr homozygous backcross 
Figure 5.  Genomic organization  of the F~ gene. 
(Tbp) Rqnesentative  genomic blot hybridized sequen- 
tially to probes derived from the 5' (FasSISg, A) and 
the 3' (FasL1R2, B) regions of the Fas gene. DNA 
samples derived from MRL- +  (lane I), MILblpr (lane 
2),  CBA-+  (hne  3),  and CBA-lpr~g (lane 4)  were 
digested with EcoRI and BamHI. Molecular weight 
size standards (in kb) are shown to the far left (top). 
(Bottom) Restriction  map of the genomic region de- 
tected by multiple Fas probes. Cleavage sites are shown 
for the restriction  enzymes EcoKl (K), BamHI (B), 
PvulI (Pv), and PstI (Ps). The position  of a 1.4-kb 
deletion associated with the lpr mutation is indicated. 
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Lymphoid mass 
Mice*  Nephritis  index*  index  Anti-dsDNA  Anti-ssDNA 
MRL-Ipr  0.97  +_  0.16s (17)ll  0.72  +_ 0.14  (17)  1.047  _+ 0.4733  (17)  1.844  _+ 0.2306  (17) 
Ft  0.10  _+ 0.14  (18)  0.02  _+  0.04  (28)  0.060  _+  0.050  (27)  0.3489  _+  0.1638  (27) 
BC  0.39  _+ 0.35  (183)  0.26  _+  0.30  (182)  0.6567  _+  0.5998  (178)  0.9291  _+  0.4924  (178) 
BC-Ipr/Ipr  0.60  _+  0.35  (86)  0.49  +_  0.29  (86)  0.7360  _+  0.5762  (84)  1.254  +  0.3948  (84) 
BC-Ipr/+  0.19  +_ 0.20  (96)  0.06  +- 0.08  (96)  0.2486  _+  0.3600  (93)  0.6459  _+  0.3955  (93) 
* The mice examined were the MILL-Ipr, (MRL-Ipr x  CAST/Ei)Ft  (FI), and the backcross (MRL-Ipr x  CAST/Ei)  x  MRL-Ipr (BC). The in- 
terspecific backcross mice were also examined in subsets defined as lpr/+ and lpr/Ipr according to their Fas locus genotype. 
* Phenotypic indices are defined in Materials and Methods. 
S SD. 
II Number of animals examined. 
mice was larger than for MRL-Ipr mice (Table 2). There was 
also a larger range of values and overlap between Ipr homozy- 
gous and Ipr/+ heterozygous backcross mice for each param- 
eter measured (Fig.  6). Although  the distribution  of values 
does not indicate a simple one- or two-gene model, the large 
variance within Ipr homozygous backcross mice nevertheless 
suggests that relatively few genes are responsible for the differ- 
ence between these mice and parental MRL-Ipr mice (see refer- 
ences 42  and  44  for relevant  discussion). 
QTL Suggest Chromosomal Locations of lpr Renal Disease 
Mod/fiers.  To determine if other loci, in addition to Fas, were 
associated with the inheritance of renal disease, we analyzed 
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5 
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Figure  6.  Histogram of the distribution of parental and backcross mice for phenotypic indexes of anti-ssDNA, anti-dsDNA, lymphoid mass, and 
nephritis. The hackcross mice (BC) were divided into lpr/+ and Ipr/Ipr  genotypes as determined by a Fas RFLP. The height of each column represents 
the number of mice with the indicated value. ([]) BC lpr/+  ; (m) BC lpr/Ipr; (l~) F1; (Ira) MR.blpr. 
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Chr  Maximum interval*  LOD* score  MarkersS  Percent variancell 
cM 
1  74.3  1.0 
2  72.4  1.7 
3  55.9  1.4 
4  70.6  1.3 
5  77.7  0.6 
6  70.7  0.6 
7  79.2  3.0 (3.0) ~ 
8  39.0  0.0 
9  72.7  0.2 
10  53.5  0.9 
11  62.3  0.1 
12  61.8  2.9  (3.9)** 
13  61.1  0.0 
14  23.4  0.6 
15  62.0  0.1 
16  31.0  0.1 
17  26.8  0.1 
18  31.4  0.1 
19  43.9  17.4 
3 
Cog (M. castaneus)  I  5 
Mine (M. castaneus)  4 
Rpl18rs9 (MRL)  4 
Pkcg-Otf-2 (MRL)  8  (24)*) 
D12Nyu3-DI2Sell (MRL) 
Fas (MRL)  37 
10 (38)U 
* Interval from most proximal to most distal marker that  was examined for each chromosome. 
) Maximum LOD score on each chromosome when  the interspecific backcross mice were examined for variance of the renal index. 
S Markers closest to the maximum LOD score are shown for those chromosomes in which a LOD score of at least 1.0 was reached. 
II The percent variance explained by the putative QTL. 
I The parental strain associated with disease. 
** LOD score for analysis of only backcross mice homozygous for the MtLL-lpr Fas RFLP. 
#) The percent variance explained by the putative QTL when only those backcross mice homozygous for the MRL-Ipr Fas RFLP were examined. 
Chr  7  LOD  SCORE  C ........... 
Pkcg 
Otf-2 
Egfbp 
Tyr 
Hrngt4-rs7 .... 
Ins-2  75.8 
Figure  7.  Histogram of LOD score values for renal disease QTL anal- 
),sis on mouse Chrs 7 and 12. 
cosegregation with polymorphic markers on each mouse au- 
tosome. X  chromosomal loci were not examined since there 
was no difference in  the  incidence  of renal disease in male 
and female progeny  (data not  shown).  A  total of 108 loci 
were analyzed that covered between 23 and 79 cM on each 
autosome  (Table 3)  and  spanned  a  total  of 1,070 cM  with 
only six intervals >25 cM. Comparison with previous genetic 
maps suggests  that  these markers cover "~75%  of the  ge- 
home at a resolution of <20 cM (M. F. Seldin, unpublished 
data). A  minimum of 110 backcross mice were typed for all 
108 loci, and 182 backcross mice were typed for 60 loci. The 
MAPMAKER  QTL program was utilized to analyze these 
data for the identification of disease modifying loci (41; see 
Materials  and  Methods). 
In addition to the region of mouse Chr 19 containing the 
Fas locus, two chromosomal regions, the proximal segment 
of mouse Chr 7 (otf-2, Pkg) and the middle segment of mouse 
Chr 12 (D12Nyu3, DI2SelI), were associated with renal dis- 
ease showing LOD scores of 3.0 and 2.9, respectively (Table 
3). The MRL-Ipr haplotype was overrepresented in those mice 
with high nephritis indices and under  represented  in those 
mice with low nephritis indices. When only those backcross 
1652  Identification  of M1LL-Ipr  Disease Modifying Loci mice that were Ipr homozygotes (as determined by Fas locus 
typing) were examined, the LOD score for the Chr 7 loci 
remained at 3.0 and that for the Chr 12 loci increased to 
3.9 (even though the number of mice was reduced from 182 
to 86; Table 2 and Fig. 7). Together, this analysis suggests 
that these two chromosomal regions account for >50% of 
the variance observed in the tpr homozygous backcross mice 
(Table 3). 
Discussion 
The current study confirms the conclusion of Watanabe- 
Fukunaga et al. (19) that the Fas gene contains the Ipr muta- 
tion. The Fas gene is closely linked to the Ipr mutation and 
RNA expression  was dramatically altered in tissues from lpr/ltrr 
mice. However, in contrast to previous studies (19), the cur- 
rent results indicate that Fas mKNA is produced in tissue 
from MRL-lpr mice, albeit of different size transcripts. The 
PCR results using primers that amplify sequences detecting 
a Fas deletion in genomic DNA from Ipr/1pr mice also am- 
plify additional DNA fragments from cDNA derived from 
Ipr/lpr mice, indicating that the aberrant cDNA contains an 
additional  sequence that is probably intronic. In addition, 
our genomic restriction site analyses demonstrate that lpr/Ipr 
mice have a 1.4-kb deletion within the Fas gene. Together, 
these data suggest that the Fas deletion results in the produc- 
tion of nonfunctional mRNA transcripts,  possibly due to 
splicing errors. 
The present studies also provide insight into the etiopatho- 
genesis of generalized autoimmunity  as well as critical events 
in T cell differentiation. The Fas gene is a type 1 membrane 
protein with sequence similarity to other members of a puta- 
tive family of cell surface  membrane receptors, including nerve 
growth factor receptor, CD40, and TNF receptor 1 (TNFR1) 
(39, 45). The cytoplasmic domain of Fas, presumably essen- 
tial for signal transduction, is most similar to CD40 and 
TNFK1. Because antibodies directed to Fas cell surface an- 
tigen induce apoptosis (45), these studies suggest  that the 
profound accumulation of CD4- ,CD8- ,CD3 + T cells from 
Ipr/Ipr mice results from escape of these cells from a normal 
apoptotic  process. 
A large variety of data suggest that during normal T cell 
development, both positive and negative selection takes place 
to eliminate potentially autoreactive cells (15). Although the 
double-negative cells in MRblpr mice do not appear to have 
a functional role (8), the accumulation of these cells suggests 
that other T cells escape the normal positive and/or negative 
selection process. Presumed defects in both positive and nega- 
tive selection have been observed in analysis of Ipr/lpr mice 
(16-18). The results of the current study suggest  that the 
expression of the Fas gene within the thymus may allow elimi- 
nation of potentially autoreactive T cells. Perhaps transcrip- 
tional control of the Fas gene is the first step downstream 
from the positive and/or negative selection signals. 
Although T cell abnormalities have been the major focus 
of research  on the Ipr mutation, recent adoptive transfer studies 
indicate that lpr/Ipr mice have primary defects in both B and 
T cells (46, 47). Thus, negative and/or positive selection at 
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both the T and B cell levels is probably required to prevent 
the occurrence of self-reactive  cells and autoreactive antibodies. 
Analysis of Fas gene expression during B cell ontogeny poten- 
tially can allow delineation of the role of Fas-mediated apop- 
tosis  in the determination of peripheral  T  and/or B  cell 
tolerance. 
The phenotypic analysis of interspecific backcross mice 
segregating for the Ipr mutation indicates that the manifesta- 
tions of generalized autoimmune disease in this model result 
from complex genetic interactions. This result is consistent 
with previous observations that tpr congenic mice (i.e., mice 
carrying Ipr mutation on different genetic backgrounds) differ 
in manifestations of disease (2, 7). In addition,  careful sero- 
logic analysis has indicated that subtle autoimmune disease 
can be detected in Ipr/+  heterozygotes (48). Having identified 
the likely site of the Ipr mutation, it was possible to reevaluate 
the backcross mice that could not be definitively phenotyped 
as LPR or non-LPR by either anti-DNA antibody levels or 
degree of lymphadenopathy.  These data indicate that several 
additional  genes are necessary for the full manifestation  of 
lymphadenopathy in Ipr homozygous mice and that Ipr het- 
erozygotes do have significant disease (up to 2.5 g lymphoid 
mass) provided certain background genes are present. Similar 
results were obtained in the analysis of nephritis, anti-ssDNA, 
and anti-dsDNA antibody levels. 
Single gene mutations may have profound effects on the 
pathophysiology  of many different diseases; however, most 
human and mouse diseases are the result of more complex 
hereditary factors. The ability to define markers at 10-20-cM 
intervals throughout the genome has allowed several groups 
to begin elucidating complex genetic diseases. Initial studies 
of plant genetic characteristics using these techniques  (49, 
50) have  recently been extended to mammalian systems. Sev- 
eral loci have now been identified as probable disease  modifiers 
in nonobese diabetic mice (51), in salt-sensitive hypertensive 
rats (52), and in a mouse model for epilepsy (53). The cur- 
rent study adds the M1LL-Ipr autoimmune renal disease to 
this list. Typing of the (MRl~lpr  x  CAST/Ei)F1  x  MKb 
Ipr backcross mice for markers covering '~75% of the mouse 
genome indicated an association of renal disease  with the MILL 
parental haplotypes for positions  on mouse Chrs 7 and 12. 
Analysis of only backcross mice that had the 1pr/Ipr genotype 
(MR.L-Ipr Fas  homozygotes) showed  similar  results  for  a 
modifying gene being present on Chr 7 and more significant 
association for another modifying gene being present on Chr 
12. At present the position of these QTL on these chromo- 
somes is imprecisely defined. Additional breeding studies in 
which congenics are established for these regions of the ge- 
home will be necessary to further define the location of these 
Ipr renal disease modifier loci (Lrdm-1,  Chr 7; Lrdm-2,  Chr 
12). Although the current data do not exclude the Igh locus 
as a renal disease modifier on mouse Chr 12, the LOD score 
at this locus was 2.3 compared with the maximum LOD score 
of 3.9 for a gene located at a more proximal position on Chr 
12 (Fig. 7). Potential renal disease modifiers, Ot~2, an Ig tran- 
scriptional regulator (34), and T cell growth factor B1 (Tc~bl), 
a mediator of inflammation and peripheral tolerance (54, 55), 
have been mapped close to Lrdm-1 on mouse Chr 7 (56). In addition,  Tgfla3 is located in the region of Lrdm-2 on Chr 
12 (57). 
None of the other chromosomal markers analyzed had LOD 
scores >2 (Table 2). Interestingly, one potentially weak renal 
disease modifier on mouse Chr 3 (LOD,  1.4) is coincident 
with the location of a very strong NOD modifier (51), raising 
the possibility that the renal disease observed in Ipr/Ipr mice 
and  diabetes modification  in  NOD  mice may represent  a 
common genetic mechanism. In contrast to the NOD model 
(51) and previous studies of the NZB model (58, 59), in this 
study we observed no substantial effect of the MHC or TCR 
B loci on nephritis. 
Finally,  this study also may help define the pathogenesis 
of human generalized autoimmune diseases, such as SLE. Al- 
though  a profound expansion  of double-negative (CD4-, 
CD8-,CD3 §  T  cells  has  not been observed in  these pa- 
tients, the variable expression of the liar homozygous and lpr 
heterozygous genotypes observed in the current study leaves 
open the possibility that a similar defect in lymphocyte apop- 
toffs may, in part,  account for the wide array of autoanti- 
bodies that characterize SLE. Furthermore,  the localization 
of disease-modifying genes from mouse studies can be used 
to predict the chromosomal location of homologous human 
disease-modifying  loci  because of conservation  of linkage 
groups between these species (reviewed in reference 60). For 
autoimmune renal disease, the human chromosomal segments 
of interest, corresponding to Lrdm-1 and Lrdm-2, are located 
on the proximal long arm of human Chr  19 and long arm 
of human  Chr  14,  respectively. In summary,  studying the 
inheritance of complex diseases in the mouse may help define 
the complex genetics of human  autoimmune  disease. 
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Note added in proof."  Sequencing of Ipr Fas transcripts confirms that many of these transcripts contain nonex- 
onic sequence. Analysis of additional data indicate an increased LOD score (4.8) for the mouse Chr 12 
renal disease QTL. 
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